Liver disease in patients with thalassaemia major is due to various causes: haemosiderin overload may provoke hepatocyte necrosis and fibrosis'; multiple transfusions may cause repeated episodes of hepatitis that tend to become chronic.2 3 Progress made in the last decade in the general treatment of patients with thalassaemia and improvements in the organisation of centres for diagnosis and treatment of the disease indicate that it may soon be possible to postpone the onset of secondary haemochromatosis in patients with thalassaemia.
To evaluate the effects of current treatment of thalassaemia we studied systematically the histological modifications in surgical liver biopsy specimens obtained from 1976-81 in children of different ages with thalassaemia undergoing splenectomy. This study differs from our other studies on needle biopsies.23 The series of patients in the present study was not selected on the basis of suspected chronic hepatitis but consisted of patients who underwent splenectomy when liver function tests were not severely altered; in addition the biopsies were surgical and, therefore, of greater diagnostic accuracy.
Materials and methods
We examined liver biopsy specimens from 86 children with Cooley's disease attending various Italian centres for the diagnosis and treatment of thalassaemia-namely, Clinica Pediatrica, University of Milan; Galliera Hospital, Genoa; Clinica Pediatrica, University of Turin; and Santa Anna Hospital, Ferrara. The patients were aged between 3 and 16 years when splenectomry was performed according to the usual protocol.
All patients were homozygous but with different molecular defects responsible for fi -thalassaemia because of their different regional origins. It was not possible to obtain the history of each patient's liver disease; the only reliable data available were those obtained at splenectomy (Table) .
Only one of the 86 children presented with positive hepatitis B serum antigen (HBsAg), which subsequently remained positive for about 10 years. In the course of liver biopsies performed during splenectomy in children with thalassaemia we found four types of lesion in various combinationsnamely, siderosis (constant and massive), hepatic foci of haemopoiesis (mainly in the youger patients), fibrosis in all stages up to cirrhosis, and hepatitis.
As the final development of liver disease in patients with thalassaemia is cirrhosis, we have given particular attention to the evolution of cirrhosis as well as to the alterations that precede it or that may accelerate its evolution. In the younger patients with thalassaemia (3-5 years old) fibrosis was generally limited to the portal spaces that appeared enlarged; later generally active septa appeared (Fig. 1) , which formed portoportal and centroportal bridges. These septa delimited the liver parenchyma in areas in which atypical liver cell regeneration produicing pseudolobules was subsequently observed (Fig. 2) . This evolution towards cirrhosis was progressive with age ( Fig. 3) : there was a minimum increase in fibrotic tissue in liver biopsy specimens only in the patients of 3-5 years; in those over 11 years old cirrhosis was common (11 out of 25); and at 15-16 years old most showed cirrhosis. Furthermore, in some patients the onset of cirrhosis was particularly early (8-9 years). It was not possible to identify causes favouring this phenomenon: in fact these children did not differ appreciably from those in whom cirrhosis developed later in the number of transfusions received, the number of previous episodes of acute hepatitis, or the inflammatory histological picture; also the patterns of the hepatitis B virus markers were similar.
Portal spaces and newly formed septa were usually the sites of inflammatory infiltrates, which consisted of lymphocytes, plasma cells, fibroblasts, and macrophages full of haemosiderin. In addition, Fig. 2 These observations underline the fact that in patients with thalassaemia the problems connected with progressive liver impairment are becoming increasingly serious, especially now that improved transfusion and support treatment delay the onset of heart failure. Possible ways of delaying the evolution of liver disease that in patients with thalassaemia develops into cirrhosis, include treatment with desferrioxamine given subcutaneously with continuous infusion pumps,13 vaccination against hepatitis virus, and antiviral drugs; the usefulness of steroids still seems rather limited even in cases which suggest aggressive hepatitis.3
In conclusion, we believe that our findings accurately reflect the likely development of liver disease in patients with thalassaemia in north Italy in the years 1976-81. They thus may serve as a reference from which to evaluate the efficacy of new methods of treatment, better health care, and better social services in improving the prognosis of patients with thalassaemia.
